All News

Conv3.jpg

EULAR 2022 Featured Industry Abstracts

Jack Cush, MD

Below is a collection of several EULAR 2022 abstracts highlighted in recent press releases from companies sponsoring major clinical trials. You can search the EULAR site for these abstract and others here.

Read Article
PSS.scleroderma.arthritis.contractures

Immune Checkpoint Inhibitor Associated Arthritis

Jack Cush, MD

Immune checkpoint inhibitors (ICIs) have dramatically improved outcomes in numerous cancers but have been hampered by a growing spectrum of immune-related adverse events (irAEs). Rheumatic complaints may be less frequent than other irAEs associated with ICI in cancer patients. 

Read Article
xray-of-hands-1526780.jpg

Bridge Prednisone Use Fails to Improve Outcomes

Jack Cush, MD

A one year, X-ray outcome trial has shown that the initial use of prednisone (high or low dose) in newly treated active early rheumatoid arthritis (RA) did not improve radiographic outcomes.

Read Article
RNL22 RA Best Management

RNL 2022: Rheumatoid Arthritis - Best Management

Jack Cush, MD

This week's Tuesday Night Rheumatology, hosted by Dr. Jack Cush, featured highlights from the 2022 RheumNow Live Rheumatoid Arthritis - Best Management Pod, followed by a lively audience Q & A. Lectures featured:

Read Article
labs2.jpg

To TDM or Not in Rheumatology?

Jack Cush, MD

Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists.

Read Article
RheumNow Podcast square

The Inflammation Reflex (5.20.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, neuroimmunology leading to therapy, the cold shoulder approach and Regulatory updates from the FDA.

Read Article
#EULAR2022 RA updated reccs w/ minor changes: start MTX+GC, reduce GC rapidly, JAKi are recc only for pts w/o risk factors for CV or malignant dz (not sure I agree with this last one if the JAKi is the best drug for the pt and there are little options avail) @rheumnow https://t.co/CXyyCi6LVI
TheDaoIndex KDAO2011 ( View Tweet)
After the #EULAR2022 Recommendations session, it begs the question - Do we follow it? In Germany, the answer is sometimes Early bDMARD or JAKi is more frequent in recent years. 1/3 of patients did not receive recommended treatment escalation after 1st csDMARD POS0234 @Rheumnow https://t.co/0DaP5b7Htc
Eric Dein ericdeinmd ( View Tweet)
Novel patient self-drawn capillary (CAP) tube blood testing for CRP/RF/CCP - YES, Pt does this at home! 49/50 seropos.RA pts successfully collected samples; , correlations w/ venous blood=excellent: CRP (0.992), CCP (0.984), RF (0.994) https://t.co/zLiwEpiyi9 Conclusions

Links:

Dr. John Cush RheumNow ( View Tweet)

Watch: Treatment Choices in Refractory RA Dr. Cush presents Treatment Choices in Refractory RA, during the RheumNow Live 2022 meeting held in March 2022. #MedEd https://t.co/5wjLyVAS7o https://t.co/dnh8Y5Of4G

Links:

Dr. John Cush RheumNow ( View Tweet)
To TDM or Not in Rheumatology? Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists. But now, EULAR has a recommendation... https://t.co/u86Vd8bFGr #MedEdTwitter https://t.co/IpKqPoWM9R

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Adherence to Rheumatoid Therapies Dr. Michaud presents Adherence to Rheumatoid Therapies at the RheumNow Live 2022 meeting held in March. #MedEd https://t.co/sCCnx82ptN https://t.co/GJE0Ktwm7B

Links:

Dr. John Cush RheumNow ( View Tweet)
A Roadmap for Investigating Preclinical Autoimmunity Using Patient-Oriented and Epidemiologic Study Designs: Example of Rheumatoid Arthritis - a comprehensive overview of studies of preclinical RA and risk of RA https://t.co/DKbDXkvFyQ

Links:

Dr. John Cush RheumNow ( View Tweet)

It's our 8th year covering this important meeting! Join us June 1 - 4 for key opinion leader perspectives, clinical trial highlights and more, as we cover #EULAR2022. https://t.co/eHziBN3TWk
Dr. John Cush RheumNow ( View Tweet)
Study of 282 inflammatory arthritis (IA) pts Rx with TNFi, 11 (3/9%) had neutralizing anti-drug Abs (nADAb). nADAb+ was more likely in smokders; such had significantly worse Dz activity, physical function, & inflammatory markers https://t.co/TnEKGpTQ85 https://t.co/I0hv5X35P1

Links:

Dr. John Cush RheumNow ( View Tweet)
VA and Marketscan data analysis ~345k RA pts shows multimorbidity increased in RA; over-represented are cardiopulmonary, cardiometabolic, and mental health and chronic pain disorders (OR 1.17 - 2.96). https://t.co/awcGQPAdiN https://t.co/c4mLkDzvCM

Links:

Dr. John Cush RheumNow ( View Tweet)
Inflammatory Arthritis Spread by ATP and Neural Crosstalk A novel study suggests that a reflex neural signaling at sites of inflammation may lead to spread to other inflammatory sites via and ATP-mediated neural crosstalk. https://t.co/vaFjqCPKtp https://t.co/RQV6qFh1pw

Links:

Dr. John Cush RheumNow ( View Tweet)
Multimorbidity Burden in Rheumatoid Arthritis Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA. https://t.co/O5U6VXalwa https://t.co/BzXyMGz0ms

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us on May 24 at 7pm for Tuesday Night Rheumatology: RA - Best Management We’ll focus on: Drug Cycling Vs Switching in RA Janet Pope, MD, MPH, FRCPC Multimorbidity in RA Elena Myasoedova, MD, PhD Preventing RA Karen Costenbader, MD https://t.co/Vc5uECptIo https://t.co/fu3qACdHkL

Links:

Dr. John Cush RheumNow ( View Tweet)
From 4 Nordic Registries, 24083 RA patients starting 41K courses of bDMARDs shows RA patients had an 80% higher risk of acute coronary syndromes than in the general population. ACS risk on bDMARDs did not improve at 3yrs or 5 yrs https://t.co/TX3jnIXkrW https://t.co/I34UvWH3qd

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×